Stay updated on Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov record for the PEMDAC study is displayed, describing a completed Phase 2 trial of pembrolizumab with entinostat for metastatic uveal melanoma, including its participant criteria, study design, and outcomes.SummaryDifference43%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH notice announces updates and explains that the agency is transitioning from the term “Artificial Intelligence” to “Super Intelligence”.SummaryDifference1%

- Check32 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check53 days agoChange DetectedAccess to the study record NCT02697630 (PEMDAC) on ClinicalTrials.gov now renders a 403 Forbidden error, replacing the previous study content. As a result, the study overview, eligibility criteria, locations, and results are not accessible to users.SummaryDifference17%

Stay in the know with updates to Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.